S2-E30 – The Global Liver institute US NASH Action Plan — What It Is and How We All Can Help Support It

Global Liver Institute Director of Global Policy Andrew Scott walks a diverse set of stakeholders through the US NASH Action Plan, with special focus on education, awareness and clarity in diagnosis and treatment.

In addition to Andrew, Becky Taub, Madrigal Pharmaceuticals co-founder, Director, CMO and President of Research & Development and Dr.Michael Fuchs, Acting Chief of the Division of Gastroenterology and Hepatology and the Central Virginia VA Health Care System, joined Stephen Harrison, Louise Campbell and Roger Green to discuss Global Liver Institute’s US NASH Action Plan. Andrew led a discussion of the plan’s four major focus areas, while the Surfers and guests discussed what they consider key needs and opportunities in each area.

This episode is sponsored with a grant from Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is leading the field of NASH therapeutic development with resmetirom, a thyroid receptor beta agonist with potential to address both the liver pathophysiology and fibrosis caused by NASH.

TOPICS: AASLD, cirrhosis, COVID-19, Diagnostic Tests, Drug Trial, education, FDA, Madrigal, NAFLD, NASH, non-invasive liver testing, Patient Advocacy, PNAFLD,

Surfing The NASH Tsunami is brought to you by HEP Dynamics
#HEPdynamics #SurfingNASH #podcast

Request A Transcript of This Episode
Request Transcript
First
Last

Ask Our Panelists A Question…

Podcast Quesitonaire
Is your question directed towards one of our panelists?

If your question is answered in our next Podcast, would you like be tagged?

Join The Discussion!

Subscribe to our free emails. Receive access to our Discussion Group. Ask your questions directly to our "Surfers"